Inhibitory effects of class I antiarrhythmic agents on Na+ and Ca2+ currents of human iPS cell-derived cardiomyocytes. 2019

Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan.

BACKGROUND Human induced pluripotent stem cells (hiPSCs) harboring cardiac myosin heavy chain 6 promoter can differentiate into functional cardiomyocytes called "iCell cardiomyocytes" under blasticidin treatment condition. While iCell cardiomyocytes are expected to be used for predicting cardiotoxicity of drugs, their responses to antiarrhythmic agents remain to be elucidated. We first examined electrophysiological properties of iCell cardiomyocytes and mRNA levels of ion channels and Ca handling proteins, and then evaluated effects of class I antiarrhythmic agents on their Na+ and Ca2+ currents. METHODS iCell cardiomyocytes were cultured for 8-14 days (38-44 days after inducing their differentiation), according to the manufacturer's protocol. We determined their action potentials (APs) and sarcolemmal ionic currents using whole-cell patch clamp techniques, and also mRNA levels of ion channels and Ca handling proteins by RT-PCR. Effects of three class I antiarrhythmic agents, pirmenol, pilsicainide and mexiletine, on Na+ channel current (INa) and L-type Ca2+ channel current (ICaL) were evaluated by the whole-cell patch clamp. RESULTS iCell cardiomyocytes revealed sinoatrial node-type (18%), atrial-type (18%) and ventricular-type (64%) spontaneous APs. The maximum peak amplitudes of INa, ICaL, and rapidly-activating delayed-rectifier K+ channel current were -62.7 ± 13.7, -8.1 ± 0.7, and 3.0 ± 1.0 pA/pF, respectively. The hyperpolarization-activated cation channel and inward-rectifier K+ channel currents were observed, whereas the T-type Ca2+ channel or slowly-activating delayed-rectifier K+ channel current was not detectable. mRNAs of Nav1.5, Cav1.2, Kir2.1, HCN4, KvLQT1, hERG and SERCA2 were detected, while that of HCN1, minK or MiRP was not. The class Ia antiarrhythmic agent pirmenol and class Ic agent pilsicainide blocked INa in a concentration-dependent manner with IC50 of 0.87 ± 0.37 and 0.88 ± 0.16 μM, respectively; the class Ib agent mexiletine revealed weak INa block with a higher IC50 of 30.0 ± 3.0 μM. Pirmenol, pilsicainide and mexiletine blocked ICaL with IC50 of 2.00 ± 0.39, 7.7 ± 2.5 and 5.0 ± 0.1 μM, respectively. CONCLUSIONS In iCell cardiomyocytes, INa was blocked by the class Ia and Ic antiarrhythmic agents and ICaL was blocked by all the class I agents within the ranges of clinical concentrations, suggesting their cardiotoxicity.

UI MeSH Term Description Entries

Related Publications

Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
January 1985, Drugs,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
July 2016, Pflugers Archiv : European journal of physiology,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
March 1992, Arzneimittel-Forschung,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
March 2021, Annals of translational medicine,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
March 1988, Japanese circulation journal,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
January 2024, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
May 2024, Scientific reports,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
September 2021, The Keio journal of medicine,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
March 1996, Journal of cardiovascular pharmacology,
Sayaka Yonemizu, and Keiichiro Masuda, and Yasutaka Kurata, and Tomomi Notsu, and Yuhei Higashi, and Kenta Fukumura, and Peili Li, and Haruaki Ninomiya, and Junichiro Miake, and Motokazu Tsuneto, and Yasuaki Shirayoshi, and Ichiro Hisatome
December 2017, Circulation research,
Copied contents to your clipboard!